HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.